|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.4000 - 2.5831|
|52 Week Range||1.4800 - 5.0000|
|Beta (3Y Monthly)||2.55|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
OTCQX:EMHTF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms”), has entered into a credit agreement with Bank of Montreal (“BMO”) as agent and lead lender and Farm Credit Canada (“FCC”) as lender (together with BMO, the “Lenders”) in respect of a CAD$20 million secured non-revolving term loan (the “Credit Facility”). Pure Sunfarms intends to use the funds available under the Credit Facility to finance the final costs of converting its 1.1 million square foot greenhouse for cannabis production, the vast majority of which was completed in January of this year. The funds available under the Credit Facility may also be used for general corporate purposes.
OTCQX:EMHTF) today announced its cannabis joint venture, Pure Sunfarms Corp. (“Pure Sunfarms”), has through a competitive process been selected by and entered into a supply agreement with the Ontario Cannabis Retail Corporation, operating as the Ontario Cannabis Store (“OCS”), to supply the OCS with Pure Sunfarms-branded cannabis products for the non-medical market in the Province of Ontario.
As we see an increase in agricultural technology being used to increase the yield, and quality, of cannabis products, companies across the space will have greater access to inventory to distribute their products. Considering the fact that legal marijuana is becoming a reality in a large portion of the United States, Canada, and abroad, investors that have historically written off cannabis companies, are now flocking in droves with excitement. Nabis Holdings (INNPF) (NAB), Emerald Health Therapeutics Inc (EMHTF) (EMH.V), Green Growth Brands Inc (GGBXF), and The Supreme Cannabis Company (SPRWF) are four cannabis companies worth keeping on your radar on Thursday.
OTCQX:EMHTF) has entered into a license with Indena S.p.A. (“Indena”) of Milan, Italy, bearing certain exclusivity rights in Canada to use Indena’s cannabidiol (“CBD”) extraction technology, and contract manufacturing services for CBD extraction. In addition, Emerald has obtained exclusive use of Indena’s proprietary Phytosome® technology for the purpose of developing novel cannabinoid-based products with superior utility, subject to a minimum volume agreement.
CORAL GABLES, FL / ACCESSWIRE / February 4, 2019 / Marijuana stocks have managed to become one of the hottest topics in the news over the course of the past few years. The fact of the matter is that previously conceived notions on cannabis are being replaced by favorable public opinions supporting all possible uses of marijuana, namely as a means of treatment for patients suffering from a myriad of ailments. Global Consortium Inc (GCGX), Emerald Health Therapeutics Inc (EMHTF) (EMH.V), Trulieve Cannabis Corp (OTC PINK: TCNNF), and OrganiGram Holdings Inc (OGRMF) are four pot stocks looking to remain on high this month.
OTCQX:EMHTF) announced today that its wholly-owned subsidiary, Verdélite Sciences Inc. (“Verdélite”), which operates a 75,000 square foot indoor cannabis cultivation facility in St.-Eustache, Quebec, has entered into a release, discharge and transaction agreement settling all claims made by Pivot Pharmaceuticals Inc. (“Pivot”) against Verdélite and its former shareholders, as described in Emerald’s most recent MD&A. The claims relate to a non-binding letter of intent which Verdélite and its former shareholders had previously entered into with Pivot with respect to a potential sale of Verdélite.
One of the best indicators to look for when investing in marijuana companies is looking into the innovative efforts taken by a given company to develop and distribute the best possible product for the market. As we continue to move through this new year, the hopes are that the cannabis industry will be able to see even more gains in the future. Nabis Holdings (INNPF) (NAB), Emerald Health Therapeutics Inc (EMHTF), Curaleaf Holdings Inc (OTC PINK: CURLF), and Wayland Group Corp (MRRCF) are 4 pot stocks gaining speed on Tuesday.
OTCQX:EMHTF) today announced that its joint venture partner, San Diego-based Emerald Health Bioceuticals (“EHB”), has launched its award-winning Endo products in Whole Foods Markets across the United States, highlighting the unique positioning and opportunity for this product line when it is launched in Canada in 2019. The joint venture, called Emerald Health Naturals (“EHN”), secured Canadian distribution rights for this product line that was developed to support the body’s endocannabinoid system (ECS), but which does not contain cannabis. Canadian retailers have not been announced.
OTCQX:EMHTF) announced that its 50%-owned joint venture focused on large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada its sixth amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. The additional approximately 138,000 square feet brings Pure Sunfarms’ total licensed cannabis production area to approximately 825,000 square feet. The newly licensed area is expected to be fully planted and in production this week.
OTCQX:EMHTF) is pleased to announce that, further to its news releases dated April 17, 2018 and November 19, 2018, it has closed its 51:49 joint venture (the “Joint Venture”) with San Diego-based Emerald Health Bioceuticals (“EHB”), called Emerald Health Naturals (“EHN”).
CORAL GABLES, FL / ACCESSWIRE / January 8, 2019 / The beginning of the new year has already gotten off to a swift start for growth in the marijuana industry. With the new year in full swing, Leafbuyer Technologies Inc (OTC:LBUY), Emerald Health Therapeutics Inc (EMHTF), Tilray Inc (TLRY), and HEXO Corp (OTC PINK: HYYDF) (HEXO.TO) represent 4 pot stocks that are heating up on Tuesday. Leafbuyer Technologies Inc (OTC:LBUY) is a company you may not have heard of, but could greatly benefit from looking into.
CORAL GABLES, FL / ACCESSWIRE / January 7, 2019 / The cannabis industry has been notoriously successful over the course of the past several years. With the recent increase in capital and sheer amount of businesses entering the market, the nascent sector has seen unprecedented growth. As public opinion surrounding cannabis becomes increasingly more favorable, the marijuana industry may begin to present an appealing opportunity for investors looking into space.
Investors (MJ) have even lost money in Aphria (APHA), Emerald Health (EMHTF), and Aurora Cannabis (ACBFF), which have lost 64%, 60%, and 37% during the same period, respectively. Analysts’ consensus target price for Supreme Cannabis remained unchanged month-over-month at 3.63 Canadian dollars. The stock closed at ~1 Canadian dollars on December 19, which was at a discount of nearly 72.5%.
OTCQX:EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada the fifth amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. With an added approximately 137,000 square feet (half of Quadrant 3), the total licensed cannabis production area is approximately 687,000 square feet. The newly licensed area is expected to be fully planted by the end of this week.
This has been a big year for production and product line expansion, but it doesn't necessarily make this marijuana stock a buy.
OTCQX: EMHTF) today announced that its joint venture, Emerald Health Naturals (“EHN”), has received product licenses and natural product numbers (NPNs) from Health Canada to sell its award-winning Endo product line of endocannabinoid-supporting nutritional products in Canada. The Endo product line has been designed to impact stress, anxiety, restless sleep, pain and other conditions using non-cannabis ingredients.
Emerald Health Therapeutics, Inc. (EMH.V) ("Emerald" or the “Company”) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Lead Investor”) under which the Lead Investor has agreed, subject to certain customary conditions, to purchase 4,000,000 common shares of the Company (the "Common Shares") at a price of $2.70 per Common Share for gross proceeds of $10,800,000 (the "Offering"). The Offering may be increased by an additional 600,000 Common Shares for total aggregate gross proceeds of up to $12,420,000.
On November 29, Canopy Growth (WEED) entered an 18-month supply agreement with MediPharm Labs, in which the latter will supply up to 900 kilograms of cannabis extract to Canopy Growth and its subsidiaries for sale. Initially, Canopy Growth committed to a minimum purchase of 450 kilograms, which could later be extended to another 450 kilograms.
OTCQX:EMHTF) announced today that Dr. Avtar Dhillon, Executive Chairman, has been appointed President of Emerald and that Chris Wagner has stepped down as CEO. As Executive Chairman, Dr. Dhillon has been intimately involved in setting the Company’s strategy and overseeing its operations.
NEW YORK, NY / ACCESSWIRE / November 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Emerald Health Therapeutics, Inc. (EMHTF), a licensed Canadian producer of cannabis. From an industry perspective, the recent legalization of cannabis sales for adult recreational use in Canada was a watershed moment for the entire industry and the Company.